How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Cancer Neoantigens: Mechanisms, Immune Recognition, and Therapeutic Frontiers

Download the full article (PDF)

The concept that the immune system can recognize and eliminate malignant cells dates back over a century, but the molecular basis for this immune surveillance was only clarified with the advent of next-generation sequencing and immunopeptidomics. Among the various molecular determinants of tumor immunogenicity, cancer neoantigens have emerged as central players in orchestrating effective immune responses. Cancer neoantigens, peptides derived from tumor-specific genetic alterations represent a distinct class of antigens that play a pivotal role in antitumor immunity. These peptides are absent from the normal human proteome and therefore escape central tolerance, allowing them to elicit potent and specific immune responses. The discovery of neoantigens has transformed our understanding of cancer immunology and provided new opportunities for precision immunotherapy. Unlike tumor-associated antigens (TAAs), which may also be found in normal tissues, neoantigens are entirely tumor-specific and result from somatic mutations within the cancer genome. This lack of expression in normal tissues renders them highly immunogenic and attractive as therapeutic targets. Neoantigen discovery and analysis are now integral to precision oncology, enabling personalized cancer vaccines, adoptive T cell therapies, and predictive biomarkers of response to immunotherapy. The following sections examine in detail the biology, immunological mechanisms, and therapeutic exploitation of cancer neoantigens.

Molecular Basis of Cancer Neoantigens

Neoantigens arise from somatic alterations in the tumor genome that alter the amino acid sequences of expressed proteins. Common sources include single-nucleotide variants (SNVs), insertions and deletions (indels), gene fusions, and abnormal splicing events. These mutations generate novel peptide sequences that are processed and presented on the tumor cell surface by major histocompatibility complex (MHC) molecules. The pathway for neoantigen generation and presentation involves several steps:

Stage	Process Description
Mutation Generation	Somatic mutations in coding regions of tumor DNA produce altered proteins containing non-synonymous amino acid substitutions.
Protein Degradation	Mutated proteins are degraded by the proteasome into short peptide fragments.
Peptide Transport	Peptides are transported into the endoplasmic reticulum (ER) by transporter associated with antigen processing (TAP) proteins.
MHC Loading	Peptides bind to MHC class I or class II molecules, depending on cell type, their length and processing pathway.
Surface Presentation	Peptide-MHC complexes are transported to the tumor cell surface, where they are recognized by T cells.

Because the immune system has not been tolerized to these novel peptides during thymic development, T cells capable of recognizing them often remain in the repertoire. The resulting recognition triggers robust immune activation and targeted cytotoxicity.

Immune Recognition of Neoantigens

The recognition of neoantigens by the immune system is mediated through the interaction of T cell receptors (TCRs) with peptide-MHC complexes. This process engages both the innate and adaptive immune systems, although adaptive immunity plays the dominant role in mediating tumor rejection.

Antigen Presentation Pathways

MHC Class I Pathway: Presents peptides derived from cytosolic proteins (typically 8–11 amino acids) to CD8⁺ cytotoxic T cells. This pathway is critical for direct recognition and killing of tumor cells. MHC class I is expressed by all cell types.
MHC Class II Pathway: Presents extracellularly derived peptides (13–25 amino acids) to CD4⁺ helper T cells, which provide cytokine support and enhance CD8⁺ T cell activity. MHC class II is mainly expressed by professional antigen presenting cells (APCs) such as dendritic cells, macrophages and also by B lymphocytes.

The strength of TCR–neoantigen interaction determines the magnitude of the immune response. High-affinity interactions typically result in clonal expansion of reactive T cells and the development of immunological memory.

Cellular Immune Response to Neoantigen Recognition

Upon recognition of a neoantigen, T cells initiate a multi-step immune cascade involving effector functions and cytokine signaling. CD8⁺ cytotoxic T lymphocytes (CTLs) are the primary effectors, directly lysing tumor cells via perforin (pokes holes in the membrane) and granzyme release (a toxin). These cytolytic proteins induce apoptosis in target cells. CD4⁺ helper T cells secrete cytokines such as interferon-gamma (IFN-γ) and interleukin-2 (IL-2), which amplify the CTL response and recruit additional immune cells to the tumor site. Dendritic cells continue to present antigens, maintaining T cell activation, while macrophages and natural killer (NK) cells contribute to tumor destruction through cytokine-mediated and antibody-dependent cytotoxic mechanisms.

Immune Cell	Primary Function in Neoantigen Response
CD8⁺ Cytotoxic T Cells	Induce apoptosis in tumor cells expressing neoantigens.
CD4⁺ Helper T Cells	Secrete cytokines to promote T cell proliferation and activation.
Dendritic Cells	Maintain antigen presentation and stimulate T cell activation.
Macrophages/NK Cells	Enhance tumor cell killing and shape the inflammatory microenvironment.

Long-lived memory T cells can persist after initial tumor clearance, enabling rapid response upon tumor recurrence.

Role of Neoantigens in the Cancer Immune Response

Neoantigens function as immunological “flags” that distinguish tumor cells from healthy tissues. The density and diversity of neoantigens within a tumor largely determine their immunogenicity and responsiveness to immunotherapy. Tumors with a high mutational burden, such as melanoma or lung carcinoma, often exhibit increased T cell infiltration and greater sensitivity to checkpoint blockade therapy. However, immune pressure can lead to immunoediting, a process comprising three phases: elimination, equilibrium, and escape. During elimination, highly immunogenic tumor clones are destroyed by T cells. In the equilibrium phase, residual variants with reduced antigenicity persist under immune surveillance. Eventually, in the escape phase, tumor clones that have lost antigen presentation capacity or express non-immunogenic neoantigens expand, leading to immune evasion and tumor growth.

Immune Evasion and Suppression of Neoantigen Responses

Tumors employ sophisticated mechanisms to avoid immune destruction despite presenting neoantigens. These mechanisms act at multiple levels of the immune response.

Mechanism	Description
Checkpoint Pathways	Tumors upregulate inhibitory ligands such as PD-L1 or CTLA-4 to suppress T cell activation.
Immunosuppressive Cells	Regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) secrete IL-10 and TGF-β, dampening effector T cell responses.
Loss of Antigen Presentation	Mutations or downregulation of MHC molecules and antigen-processing components reduce neoantigen visibility.
Metabolic Constraints	Tumor microenvironments deplete nutrients like glucose and tryptophan, impairing T cell metabolism and function.
Immunoediting	Selection for tumor clones lacking immunogenic neoantigens results in immune escape and tumor progression.

These mechanisms form the biological basis for resistance to immunotherapy and remain targets for therapeutic intervention.

Therapeutic Applications of Neoantigens

Neoantigen-based therapies exploit the tumor-specific nature of these antigens to generate targeted immune responses. They represent one of the most promising approaches to personalized cancer treatment.

Neoantigen Vaccines

Neoantigen vaccines are designed from patient-specific tumor mutations identified via sequencing. The vaccines may consist of synthetic peptides, mRNA, or dendritic cells pulsed with neoantigen peptides. Their goal is to stimulate both CD8⁺ and CD4⁺ T cell responses. Clinical trials have demonstrated encouraging results in melanoma, glioblastoma, and non–small cell lung cancer, showing induction of durable T cell immunity and delayed disease progression.

Adoptive T Cell Therapy

Adoptive cell therapy (ACT) involves expanding or engineering T cells that target specific neoantigens. In TCR-T therapy, patient-derived T cells are modified to express high-affinity TCRs specific for identified neoantigens. Alternatively, tumor-infiltrating lymphocyte (TIL) therapy expands naturally occurring neoantigen-reactive T cells from tumor biopsies. These approaches have achieved significant clinical responses in patients with advanced solid tumors.

Combination Approaches

Neoantigen vaccines and adoptive T cell therapies are often combined with immune checkpoint inhibitors to overcome T cell exhaustion. Checkpoint blockade (anti–PD-1, anti–CTLA-4) synergizes with neoantigen-targeted therapies by sustaining effector T cell function within the tumor microenvironment.

Recent Advances in Neoantigen-Based Cancer Therapy

Recent technological and conceptual advances have accelerated the clinical translation of neoantigen-based therapies. Machine learning algorithms now predict which mutations are most likely to generate immunogenic peptides based on MHC binding affinity and expression data. mRNA-based vaccine platforms, validated during the COVID-19 pandemic, have been adapted for cancer immunotherapy to encode multiple patient-specific neoantigens within a single construct. Clinical trials of such vaccines have demonstrated strong neoantigen-specific T cell responses and favorable safety profiles. Furthermore, CRISPR-Cas9 genome editing is being utilized to engineer T cells with neoantigen-specific receptors of defined affinity, improving both specificity and persistence. Efforts are also underway to identify shared or public neoantigens, mutations that recur across patients and tumor types, allowing for the creation of semi-personalized or “off-the-shelf” therapies that retain specificity while reducing cost and manufacturing time.

Neoantigen Analysis and Precision Oncology

Neoantigen analysis integrates genomic, transcriptomic, and immunopeptidomic data to characterize a patient’s unique tumor antigen landscape. This information is essential for selecting optimal targets for immunotherapy.

Analytical Application	Clinical Benefit
Neoantigen Load Quantification	Predicts responsiveness to immune checkpoint blockade.
Neoantigen-Specific T Cell Tracking	Monitors immune responses and potential relapse.
In Silico Epitope Prediction	Accelerates vaccine and TCR design by identifying high-affinity neoantigens.
Multi-Omics Integration	Enhances accuracy and reduces false-positive neoantigen predictions.

By tailoring therapies to each patient’s mutational and immunological profile, neoantigen analysis forms the cornerstone of next-generation precision immunotherapy.

Conclusion

Cancer neoantigens embody the intersection of tumor genetics and immunology, providing an unprecedented opportunity for precise, tumor-specific therapy. They not only serve as biomarkers of immune responsiveness but also represent direct therapeutic targets. Advances in computational prediction, sequencing technologies, and vaccine engineering have rapidly advanced the field from conceptual promise to clinical implementation. The next decade will likely see neoantigen-based therapies become integral components of personalized cancer treatment, used alone or in combination with checkpoint blockade, cytokine therapy, or conventional modalities. As research continues to refine neoantigen identification and overcome immune evasion, these antigens are poised to redefine the future of cancer immunotherapy. Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

2. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1.

4. American Society of Hematology (ASH) Annual Meeting 2024. Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline. Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.